Neue radioonkologische Therapiekonzepte beim nicht metastasierten Lungenkarzinom

Zusammenfassung

Die Strahlentherapie nimmt in der Behandlung des nicht metastasierten Lungenkarzinoms eine entscheidende Rolle ein, da sie sowohl einen kurativen Therapieansatz und zudem eine Verbesserung der krankheitsbedingten Symptome bietet. Als primäre Behandlungsmethode oder als (neo-)adjuvante Therapie nach einer Operation können die Kontroll- und Überlebensraten erhöht und damit die onkologischen Therapieergebnisse verbessert werden. Moderne Techniken wie die stereotaktische Strahlentherapie (SBRT) ermöglichen ein präzises Anvisieren des Tumors, wodurch die Strahlenbelastung des gesunden Gewebes minimiert und die Behandlungsdauer verkürzt werden. Die Synergie zwischen Strahlentherapie und systemischen Behandlungen, einschl. der Immuntherapie, führt zu einer weiteren Verbesserung der Behandlungsergebnisse. Die Immuntherapie verstärkt die körpereigene Immunreaktion gegen Tumorzellen und kann so die Wirksamkeit der Strahlentherapie erhöhen. Gleichermaßen werden die Mechanismen der Immuntherapie durch das Potenzial der Strahlentherapie, die Mikroumgebung des Tumors zu modulieren, verstärkt. Daher kann eine Kombination aus Strahlen- und Immuntherapie eine bessere Tumorkontrolle und damit Überlebensvorteile für den behandelten Patienten bieten. Zusätzlich maximiert eine multidisziplinäre Therapie aus Strahlentherapie, Chirurgie und Chemotherapie/Immuntherapie die Wirksamkeit der Behandlung und minimiert zeitgleich die Toxizität. In diesem Artikel geben wir einen Überblick über moderne Behandlungstechniken der Strahlentherapie und über mögliche Entwicklungen in naher Zukunft.

Abstract

Radiotherapy plays a critical role in the management of non-metastatic lung cancer, offering curative potential and symptom relief. It serves as a primary treatment modality or adjuvant therapy post-surgery, enhancing local control and survival rates. Modern techniques like Stereotactic Body Radiotherapy (SBRT) enable precise tumor targeting, minimizing damage to healthy tissue and reducing treatment duration. The synergy between radiotherapy and systemic treatments, including immunotherapy, holds promise in improving outcomes. Immunotherapy augments the immune response against cancer cells, potentially enhancing radiotherapy’s efficacy. Furthermore, radiotherapy’s ability to modulate the tumor microenvironment complements the immunotherapy’s mechanism of action. As a result, the combination of radiotherapy and immunotherapy may offer superior tumor control and survival benefits. Moreover, the integration of radiotherapy with surgery and chemotherapy in multidisciplinary approaches maximizes treatment efficacy while minimizing toxicity. Herein we present an overview on modern radiotherapy and potential developments in the close future.

Schlüsselwörter

stereotaktische Strahlentherapie - nicht kleinzelliger Lungenkarzinom - Immuntherapie - Multidisziplin

Keywords

stereotactic body radiation therapy - non-small cell lung cancer - immunotherapy - multidiscipline

Publication History

Received: 29 April 2024

Accepted after revision: 15 July 2024

Article published online:
13 August 2024

• Literatur

• 1 Potters L, Kavanagh B, Galvin JM. et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010; 76: 326-332
• 2 Amin SA, Alam M, Baine MJ. et al. The impact of stereotactic body radiation therapy on the overall survival of patients diagnosed with early-stage non-small cell lung cancer. Radiother Oncol 2021; 155: 254-260
• 3 Timmerman RD, Hu C, Michalski JM. et al. Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer. JAMA Oncol 2018; 4: 1287-1288
• 4 Videtic GM, Paulus R, Singh AK. et al. Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2019; 103: 1077-1084
• 5 Nyman J, Hallqvist A, Lund JA. et al. SPACE – A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiother Oncol 2016; 121: 1-8
• 6 Swaminath A, Parpia S, Wierzbicki M. et al. LUSTRE: A Phase III Randomized Trial of Stereotactic Body Radiotherapy (SBRT) vs. Conventionally Hypofractionated Radiotherapy (CRT) for Medically Inoperable Stage I Non-Small Cell Lung Cancer (NSCLC). Int J Radiat Oncol Biol Phys 2022; 114: 1061-1062
• 7 Ball D, Mai GT, Vinod S. et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol 2019; 20: 494-503
• 8 Chang JY, Senan S, Paul MA. et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 2015; 16: 630-637
• 9 Chang JY, Mehran RJ, Feng L. et al. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol 2021; 22: 1448-1457
• 10 Chen H, Laba JM, Boldt RG. et al. Stereotactic Ablative Radiation Therapy Versus Surgery in Early Lung Cancer: A Meta-analysis of Propensity Score Studies. Int J Radiat Oncol Biol Phys 2018; 101: 186-194
• 11 Palma DA, Bahig H, Hope A. et al. Stereotactic Radiation Therapy in Early Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Nonrandomized Clinical Trial. JAMA Oncol 2024; 10: 575-582
• 12 Leitlinienprogramm Onkologie, Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF. S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. AWMF-Registernummer: 020–007OL. Langversion 3.0. 2024 Accessed April 18, 2024 at: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Lungenkarzinom/Version_3/LL_Lungenkarzinom_Langversion_3.0.pdf
• 13 Timmerman RD, Paulus R, Pass HI. et al. Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial. JAMA Oncol 2018; 4: 1263-1266
• 14 Bezjak A, Paulus R, Gaspar LE. et al. Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial. J Clin Oncol 2019; 37: 1316-1325
• 15 Iyengar P, Zhang-Velten E, Court L. et al. Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial. JAMA Oncol 2021; 7: 1497-1505
• 16 Meredith EG, Filion E, Faria S. et al. Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer: A Safety and Efficacy Trial (SUNSET). Int J Radiat Oncol Biol Phys 2024;
• 17 Lindberg K, Grozman V, Karlsson K. et al. The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy. J Thorac Oncol 2021; 16: 1200-1210
• 18 Adebahr S, Collette S, Shash E. et al. LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. Br J Radiol 2015; 88: 20150036
• 19 Giuliani ME, Filion EJ, Faria S. et al. Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer: A Safety and Efficacy Trial (SUNSET). Int J Radiat Oncol Biol Phys 2024; 118: e2
• 20 Widder J, Postmus D, Ubbels JF. et al. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer. Int J Radiat Oncol Biol Phys 2011; 81: e291-e297
• 21 Wolff HB, Alberts L, Kastelijn EA. et al. Differences in Longitudinal Health Utility between Stereotactic Body Radiation Therapy and Surgery in Stage I Non-Small Cell Lung Cancer. J Thorac Oncol 2018; 13: 689-698
• 22 Nestle U, Adebahr S, Kaier K. et al. Quality of life after pulmonary stereotactic fractionated radiotherapy (SBRT): Results of the phase II STRIPE trial. Radiother Oncol 2020; 148: 82-88
• 23 Gkika E, Firat E, Adebahr S. et al. Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer. NPJ Precis Oncol 2023; 7: 24
• 24 Altorki NK, McGraw TE, Borczuk AC. et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol 2021; 22: 824-835
• 25 Chang JY, Lin SH, Dong W. et al. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet 2023; 402: 871-881
• 26 Robinson CG, Xing L, Tanaka H. et al. Phase 3 study of durvalumab with SBRT for unresected stage I/II, lymph-node negative NSCLC (PACIFIC-4/RTOG3515). J Clin Oncol 2023; 41(16 Suppl.): TPS8607
• 27 Jabbour SK, Houghton B, Robinson AG. et al. Phase 3, Randomized, Placebo-Controlled Study of Stereotactic Body Radiotherapy (SBRT) with or Without Pembrolizumab in Patients with Inoperable Stage I/IIA Non–Small-Cell Lung Cancer (NSCLC): KEYNOTE-867. Int J Radiat Oncol Biol Phys 2020; 108(3 Suppl.): E135-E136
• 28 Daly ME, Redman M, Simone CB. et al. SWOG/NRG S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab + SBRT vs. SBRT Alone in High Risk, Early-Stage NSCLC (NCT#04214262). Int J Radiat Oncol Biol Phys 2022; 114
• 29 Hallqvist A, Koyi H, de Petris L. et al. 63MO Safety analysis of durvalumab following stereotactic body radiotherapy (SBRT) in early-stage non-small cell lung cancer (NSCLC) patients: A first report of a randomized phase II trial (ASTEROID). J Thorac Oncol 2021; 16(4 Suppl.): S729-S730
• 30 Perez CA, Stanley K, Rubin P. et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer 1980; 45: 2744-2753
• 31 Aupérin A, Le Péchoux C, Rolland E. et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 2181-2190
• 32 Antonia SJ, Villegas A, Daniel D. et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 2017; 377: 1919-1929
• 33 Zhao J, Xia Y, Kaminski J. et al. Treatment-Related Death during Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Studies. PLoS One 2016; 11: e0157455
• 34 Curran jr WJ, Paulus R, Langer CJ. et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011; 103: 1452-1460
• 35 De Ruysscher D, Botterweck A, Dirx M. et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol 2009; 20: 98-102
• 36 Pallis AG, Gridelli C, Wedding U. et al. Management of elderly patients with NSCLC; updated expert’s opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. Ann Oncol 2014; 25: 1270-1283
• 37 Ramnath N, Dilling TJ, Harris LJ. et al. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143(5 Suppl.): e314S-e340S
• 38 Daly ME, Singh N, Ismaila N. et al. Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline. J Clin Oncol 2022; 40: 1356-1384
• 39 Atagi S, Mizusawa J, Ishikura S. et al. Chemoradiotherapy in Elderly Patients With Non-Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301). Clin Lung Cancer 2018; 19: e619-e627
• 40 El Sharouni SY, Kal HB, Battermann JJ. Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy. Br J Cancer 2003; 89: 2184-2189
• 41 Garassino MC, Mazieres J, Reck M. et al. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. J Thorac Oncol 2022; 17: 1415-1427
• 42 Faehling M, Schumann C, Christopoulos P. et al. Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP). Lung Cancer 2020; 150: 114-122
• 43 Girard N, Bar J, Garrido P. et al. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study. J Thorac Oncol 2023; 18: 181-193
• 44 Bradley JD, Hu C, Komaki RR. et al. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. J Clin Oncol 2020; 38: 706-714
• 45 Belderbos J, Uitterhoeve L, van Zandwijk N. et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972–22973). Eur J Cancer 2007; 43: 114-121
• 46 Maguire J, Khan I, McMenemin R. et al. SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status. Eur J Cancer 2014; 50: 2939-2949
• 47 Kaster TS, Yaremko B, Palma DA. et al. Radical-intent hypofractionated radiotherapy for locally advanced non-small-cell lung cancer: a systematic review of the literature. Clin Lung Cancer 2015; 16: 71-79
• 48 Robinson SD, Tahir BA, Absalom KAR. et al. Radical accelerated radiotherapy for non-small cell lung cancer (NSCLC): A 5-year retrospective review of two dose fractionation schedules. Radiother Oncol 2020; 143: 37-43
• 49 Guckenberger M, Belka C, Bezjak A. et al. Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. Radiother Oncol 2020; 146: 223-229
• 50 Feins RH. Multi-modality treatment of non-small cell lung cancer. Surg Clin North Am 2002; 82: 611-620
• 51 Pless M, Stupp R, Ris H. et al. Final Results of the Sakk 16/00 Trial: a Randomized Phase III Trial Comparing Neoadjuvant Chemoradiation to Chemotherapy Alone in Stage Iiia/N2 Non-Small Cell Lung Cancer (Nsclc). Ann Oncol 2014; 25 (Suppl. 4) IV417
• 52 Eberhardt WE, Pöttgen C, Gauler TC. et al. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). J Clin Oncol 2015; 33: 4194-4201
• 53 Bahce I, Dickhoff C, Schneiders FL. et al. 950O Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable lung cancer: The INCREASE trial. Ann Oncol 2022; 33 (Suppl. 7) S982
• 54 Harling L, Jayakumar S, Ashrafian H. et al. Mediastinal radiotherapy after adjuvant chemotherapy for resected non-small cell lung cancer with N2 lymphadenopathy: A novel meta-analysis. JTCVS Open 2021; 5: 121-130
• 55 Le Pechoux C, Pourel N, Barlesi F. et al. LBA3_PR An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683. Ann Oncol 2020; 31 (Suppl. 4) S1178
• 56 Hui Z, Men Y, Hu C. et al. Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial. JAMA Oncol 2021; 7: 1178-1185
• 57 Movsas B, Hu C, Sloan J. et al. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial. JAMA Oncol 2016; 2: 359-367
• 58 Woodford C, Yartsev S, Dar AR. et al. Adaptive radiotherapy planning on decreasing gross tumor volumes as seen on megavoltage computed tomography images. Int J Radiat Oncol Biol Phys 2007; 69: 1316-1322
• 59 Vera P, Thureau S, Chaumet-Riffaud P. et al. Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by¹⁸F-Misonidazole PET/CT in Patients with Non-Small Cell Lung Carcinoma (RTEP5 Study). J Nucl Med 2017; 58: 1045-1053
• 60 Vera P, Le Tinier F, Chaumet-Riffaud P. et al. 1291O Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients with inoperable stage III non-small cell lung cancer (RTEP7 – IFCT 1401): A prospective multicentre, open-label, randomised, controlled trial. Ann Oncol 2023; 34 (Suppl. 2) S745
• 61 Feddock J, Arnold SM, Shelton BJ. et al. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 2013; 85: 1325-1331
• 62 van Elmpt W, De Ruysscher D, van der Salm A. et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiother Oncol 2012; 104: 67-71
• 63 Brooks C, Miles E, Hoskin PJ. Radiotherapy trial quality assurance processes: a systematic review. Lancet Oncol 2024; 25: e104-e113
• 64 Lin SH, Lin HY, Verma V. et al. Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. Cancer Treat Res Commun 2022; 30: 100514
• 65 Herbst RS, Majem M, Barlesi F. et al. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. J Clin Oncol 2022; 40: 3383-3393
• 66 Gkika E, Benndorf M, Oerther B. et al. Immunohistochemistry and Radiomic Features for Survival Prediction in Small Cell Lung Cancer. Front Oncol 2020; 10: 1161
• 67 Carles M, Fechter T, Radicioni G. et al. FDG-PET Radiomics for Response Monitoring in Non-Small-Cell Lung Cancer Treated with Radiation Therapy. Cancers (Basel) 2021; 13: 814